CA2773527A1 - Novel biomarkers of disease histopathology - Google Patents
Novel biomarkers of disease histopathology Download PDFInfo
- Publication number
- CA2773527A1 CA2773527A1 CA2773527A CA2773527A CA2773527A1 CA 2773527 A1 CA2773527 A1 CA 2773527A1 CA 2773527 A CA2773527 A CA 2773527A CA 2773527 A CA2773527 A CA 2773527A CA 2773527 A1 CA2773527 A1 CA 2773527A1
- Authority
- CA
- Canada
- Prior art keywords
- multiple sclerosis
- protein
- fgf
- anosmin
- cns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000010099 disease Diseases 0.000 title description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 16
- 239000000101 novel biomarker Substances 0.000 title description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 144
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract description 143
- 230000003902 lesion Effects 0.000 claims abstract description 106
- 102100023086 Anosmin-1 Human genes 0.000 claims abstract description 102
- 101710188941 Anosmin-1 Proteins 0.000 claims abstract description 100
- 208000016192 Demyelinating disease Diseases 0.000 claims abstract description 75
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 68
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 64
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 57
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 239000013060 biological fluid Substances 0.000 claims abstract description 29
- 238000001514 detection method Methods 0.000 claims abstract description 25
- 230000001684 chronic effect Effects 0.000 claims description 34
- 230000006378 damage Effects 0.000 claims description 28
- 210000004884 grey matter Anatomy 0.000 claims description 28
- 239000012472 biological sample Substances 0.000 claims description 25
- 210000004885 white matter Anatomy 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 23
- 230000008499 blood brain barrier function Effects 0.000 claims description 21
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 21
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 21
- 206010012305 Demyelination Diseases 0.000 claims description 20
- 238000002965 ELISA Methods 0.000 claims description 14
- 230000001154 acute effect Effects 0.000 claims description 12
- 239000000090 biomarker Substances 0.000 claims description 12
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 11
- 238000003018 immunoassay Methods 0.000 claims description 11
- 230000000750 progressive effect Effects 0.000 claims description 11
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 claims description 10
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims description 10
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 10
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 8
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 6
- 210000001138 tear Anatomy 0.000 claims description 6
- 208000011403 Alexander disease Diseases 0.000 claims description 5
- 208000022526 Canavan disease Diseases 0.000 claims description 5
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims description 5
- 206010010252 Concentric sclerosis Diseases 0.000 claims description 5
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 5
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 5
- 208000028226 Krabbe disease Diseases 0.000 claims description 5
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 5
- 208000003926 Myelitis Diseases 0.000 claims description 5
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 201000004525 Zellweger Syndrome Diseases 0.000 claims description 5
- 208000036813 Zellweger spectrum disease Diseases 0.000 claims description 5
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 208000009885 central pontine myelinolysis Diseases 0.000 claims description 5
- 210000000877 corpus callosum Anatomy 0.000 claims description 5
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 5
- 208000009174 transverse myelitis Diseases 0.000 claims description 5
- 208000018254 acute transverse myelitis Diseases 0.000 claims description 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 4
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 4
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 description 27
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 15
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 230000003210 demyelinating effect Effects 0.000 description 15
- 208000014674 injury Diseases 0.000 description 15
- 238000005259 measurement Methods 0.000 description 14
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 210000004248 oligodendroglia Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 11
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 11
- 108010083674 Myelin Proteins Proteins 0.000 description 11
- 102000006386 Myelin Proteins Human genes 0.000 description 11
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 11
- 210000005012 myelin Anatomy 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 238000012744 immunostaining Methods 0.000 description 10
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 230000008439 repair process Effects 0.000 description 10
- 102000006354 HLA-DR Antigens Human genes 0.000 description 9
- 108010058597 HLA-DR Antigens Proteins 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 230000004075 alteration Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 210000000274 microglia Anatomy 0.000 description 8
- 210000003007 myelin sheath Anatomy 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 210000001130 astrocyte Anatomy 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000011532 immunohistochemical staining Methods 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RDFLLVCQYHQOBU-GPGGJFNDSA-O Cyanin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO)O1)c1c(-c2cc(O)c(O)cc2)[o+]c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)cc(O)c2)c1 RDFLLVCQYHQOBU-GPGGJFNDSA-O 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- RDFLLVCQYHQOBU-ZOTFFYTFSA-O cyanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RDFLLVCQYHQOBU-ZOTFFYTFSA-O 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 101001050039 Homo sapiens Anosmin-1 Proteins 0.000 description 4
- 101150038994 PDGFRA gene Proteins 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000021617 central nervous system development Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000001181 motogenic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000004786 perivascular cell Anatomy 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101150019331 FGF2 gene Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003967 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100281008 Homo sapiens FGF2 gene Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000007493 Kallmann syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000012305 analytical separation technique Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- LCPUDZUWZDSKMX-UHFFFAOYSA-K azane;hydrogen sulfate;iron(3+);sulfate;dodecahydrate Chemical compound [NH4+].O.O.O.O.O.O.O.O.O.O.O.O.[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O LCPUDZUWZDSKMX-UHFFFAOYSA-K 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002838 chemorepellent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000005088 metallography Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000011851 neurological alteration Diseases 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000007694 polyacrylamide gel isoelectric focusing Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000009237 prenatal development Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200930661 | 2009-09-07 | ||
| ES200930661A ES2356540B1 (es) | 2009-09-07 | 2009-09-07 | Método para predecir las características histopatológicas de las lesiones de un sujeto con una enfermedad desmielinizante del sistema nervioso central. |
| ESP201030090 | 2010-01-25 | ||
| ES201030090A ES2369099B1 (es) | 2010-01-25 | 2010-01-25 | La proteina Anosmina-1 como biomarcador para la clasificación histopatológica de lesiones de un sujeto con enfermedad desmielinizante del Sistema Nervioso Central. |
| PCT/ES2010/070584 WO2011045456A2 (es) | 2009-09-07 | 2010-09-07 | Nuevos biomarcadores de la histopatología de enfermedades desmielinizantes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2773527A1 true CA2773527A1 (en) | 2011-04-21 |
Family
ID=43334531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2773527A Abandoned CA2773527A1 (en) | 2009-09-07 | 2010-09-07 | Novel biomarkers of disease histopathology |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120252688A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2477030A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013504075A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010306515A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2773527A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011045456A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2762602B1 (fr) * | 1997-04-28 | 1999-06-04 | Inst Nat Sante Rech Med | Moyens pour la detection precoce de pathologies auto-immunes inflammatoires |
-
2010
- 2010-09-07 JP JP2012528396A patent/JP2013504075A/ja active Pending
- 2010-09-07 EP EP10763733A patent/EP2477030A2/en not_active Withdrawn
- 2010-09-07 AU AU2010306515A patent/AU2010306515A1/en not_active Abandoned
- 2010-09-07 CA CA2773527A patent/CA2773527A1/en not_active Abandoned
- 2010-09-07 US US13/394,501 patent/US20120252688A1/en not_active Abandoned
- 2010-09-07 WO PCT/ES2010/070584 patent/WO2011045456A2/es not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011045456A9 (es) | 2011-11-03 |
| EP2477030A2 (en) | 2012-07-18 |
| US20120252688A1 (en) | 2012-10-04 |
| WO2011045456A3 (es) | 2011-06-30 |
| JP2013504075A (ja) | 2013-02-04 |
| AU2010306515A1 (en) | 2012-04-12 |
| WO2011045456A2 (es) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12422433B2 (en) | Blood biomarker that predicts persistent cognitive dysfunction after concussion | |
| Giovannoni | Multiple sclerosis cerebrospinal fluid biomarkers | |
| KR102064060B1 (ko) | 뇌의 베타 아밀로이드 축적 감별용 혈중 바이오마커 | |
| JP2012515335A (ja) | 線維症と肝硬変を識別する手段及び方法 | |
| US20110143380A1 (en) | Alzheimer's disease biomarkers and methods of use | |
| US9977036B2 (en) | Diagnostic markers for multiple sclerosis | |
| KR20200066249A (ko) | 뇌 유래 소포체 특이적 마커 및 이를 이용한 뇌 질병 진단 방법 | |
| Agnello et al. | The value of serum glial fibrillary acidic protein as a biomarker of astrogliosis in different neurological diseases | |
| US8298784B2 (en) | In vitro procedure for diagnosis and early diagnosis of neurodegenerative diseases | |
| WO2021009074A1 (en) | Novel markers as early predictors of alzheimer's pathology | |
| JP2010507093A (ja) | バイオマーカー | |
| US20120252688A1 (en) | Novel biomarkers of disease histopathology | |
| EP3872494A1 (en) | Blood biomarker for detecting deposition of amyloid beta in brains of groups with normal cognitive function and mild cognitive impairment | |
| EP3730942A1 (en) | Diagnosis markers for atrial fibrillation | |
| ES2356540B1 (es) | Método para predecir las características histopatológicas de las lesiones de un sujeto con una enfermedad desmielinizante del sistema nervioso central. | |
| CN114137214B (zh) | 用于预测应激后精神心理症状发生的免疫检测试剂盒及应用 | |
| WO2011109503A1 (en) | Novel csf biomarkers for alzheimer's disease and frontotemporal lobar degeneration | |
| ES2369099B1 (es) | La proteina Anosmina-1 como biomarcador para la clasificación histopatológica de lesiones de un sujeto con enfermedad desmielinizante del Sistema Nervioso Central. | |
| WO2024040103A2 (en) | Methods for early diagnosis and treatment of open neural tube defects | |
| KR20140018691A (ko) | 시누클레인병증의 진단 방법 및 이를 위한 진단 키트 | |
| Yamanoi et al. | Neuro-Oncology Advances | |
| Stoop et al. | Decreased neuro-axonal proteins in CSF at first demyelinating event | |
| Pulinx et al. | Biomarker discovery in MScl | |
| AU2018219790A1 (en) | S100β and isoforms for detection of neurological conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150821 |
|
| FZDE | Dead |
Effective date: 20170907 |